BPDCN International Registry shared a post on LinkedIn:
“BPDCN affects fewer than 1 in 1,000,000 people – yet remains one of the most aggressive and misdiagnosed blood cancers. To change that, we need to share knowledge.
We’re launching BPDCN paper Of The Day – a series spotlighting the research shaping BPDCN diagnosis and management worldwide.
Paper #1 – BPDCN: 2025 Update on Diagnosis, Pathophysiology, Risk Assessment and Management
From CD123 immunophenotyping to allo-SCT consolidation – the most complete BPDCN clinical roadmap of 2025. A must-read for any clinician or researcher working in this space.
The BPDCN International Registry (NCT05430971) is actively enrolling centers worldwide. Interested in contributing data? bpdcn@immonc.org.”
Title: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management
Authors: Shai Shimony, Marlise R. Luskin, Naseema Gangat, Nicole R. LeBoeuf, Angela M. Feraco, Andrew A. Lane
Read the Full Article.
Other articles about BPDCN on OncoDaily.